Hangzhou Leap Chem Co., Ltd. is one of the most professional manufacturers and suppliers of semaglutide丨cas 910463-68-2 in China. Welcome to wholesale custom made chemical products at competitive price from our factory. For more cheap products, contact us now.
Specifications
|
Appearance |
White or off-white powder |
|
Assay |
95.0% - 105.0% (Calculated with reference to the anhydrous and salt-free substance) |
|
Solubility |
Freely soluble in water |
|
Solution Clarity And Color |
Clear and colorless |
|
Infrared Spectrum |
The infrared absorption spectrum of this sample should be consistent with the reference spectrum |
|
Specific Optical Rotation [α]29D |
-16 to -6.0° (anhydrous and sodium ion-free substance, C=10 mg/ml, H2O) |
|
Identification By HPLC |
The retention time of the principal peak of the test solution corresponds to that of the reference solution, as obtained in the assay |
|
Molecular Ion Mass |
4112.58 ~ 4114.58 Da |
|
Amino Acid Content |
Asp: 0.9 ~ 1.1; Ser: 2.7 ~ 3.3; Glu: 4.5 ~ 5.5; Gly: 3.6 ~ 4.4; His: 0.9 ~ 1.1; Arg: 1.8 ~ 2.2; Thr: 1.8 ~ 2.2; |
|
AEEA |
Should be detected |
|
pH |
6.0 ~ 9.0 |
|
Related Substances (HPLC) |
Single impurity: NMT 1.0% |
|
Purity (HPLC) |
99.0% min |
|
Sodium Ion |
1.5% - 4.0% |
|
High Molecular Weight Species |
0.5% max |
|
Dichloromethane |
600 ppm max |
|
N,N-Dimethylformamide |
880 ppm max |
|
Residual Solvents (GC) |
Acetonitrile: 410 ppm max |
|
Bacterial Endotoxins |
2 EU/mg max |
|
Total Aerobic Microbial Count (TAMC) |
200 cfu/g max |
|
Total Yeast and Mold Count (TYMC) |
100 cfu/g max |
|
Escherichia coli |
Absent |
|
Trifluoroacetate Ion |
0.1% max |
|
Acetate Ion |
0.1% max |
Transport Information
|
Parameter |
Specification |
|
UN Number |
|
|
Class |
|
|
Packing Group |
|
|
H.S. Code |
2922199090305 |
|
Stability & Reactivity |
The product is chemically stable under standard ambient conditions. |
|
Storage |
Store at -20°C |
|
Condition to Avoid |
|
|
Package |
Applications
1. Type 2 Diabetes Mellitus Treatment
Semaglutide丨CAS 910463-68-2 is primarily used as a therapeutic agent for managing type 2 diabetes.
It improves glycemic control by stimulating glucose-dependent insulin secretion and reducing glucagon levels.
Its long half-life allows for once-weekly dosing, improving patient compliance.
Marketed under brand names such as Ozempic and Rybelsus (oral form).
2. Obesity and Weight Management
Semaglutide is also approved for chronic weight management in obese or overweight patients, with or without type 2 diabetes.
It helps reduce appetite and caloric intake by acting on appetite-regulating centers in the brain.
Marketed under brand names like Wegovy for weight loss indication.
3. Cardiovascular Risk Reduction
Clinical trials have shown that semaglutide reduces the risk of major cardiovascular events in patients with type 2 diabetes and established cardiovascular disease.
This makes it an important drug for reducing morbidity and mortality in this population.
4. Research and Development
Semaglutide serves as a model molecule for developing next-generation peptide therapeutics targeting metabolic disorders.
Used in studies exploring GLP-1 receptor biology and related pathways.
Benefits
✅ 1. Effective Glycemic Control
Significantly lowers HbA1c (glycated hemoglobin), fasting glucose, and postprandial glucose levels.
Helps delay progression of diabetes and reduces the need for insulin therapy.
✅ 2. Weight Loss
Patients experience substantial weight loss, which further improves metabolic parameters and overall health.
Weight reduction helps lower blood pressure, improve lipid profiles, and decrease insulin resistance.
✅ 3. Convenient Dosing
Once-weekly subcutaneous injection or once-daily oral tablets increase treatment adherence compared to multiple daily injections of insulin or other drugs.
✅ 4. Cardioprotective Effects
Reduces cardiovascular risk factors beyond glucose control, including lowering blood pressure and improving endothelial function.
✅ 5. Favorable Safety Profile
Generally well tolerated; common side effects include mild gastrointestinal symptoms like nausea, which tend to decrease over time.
Summary
Semaglutide丨CAS 910463-68-2 is a breakthrough GLP-1 receptor agonist used primarily for type 2 diabetes management and obesity treatment. It provides effective blood sugar control, supports significant weight loss, and reduces cardiovascular risk with a convenient dosing regimen. Its benefits and safety profile make it a cornerstone in modern metabolic disease therapy.
